Business context and reporting period
Revelation Biosciences, Inc. is a clinical-stage biopharmaceutical company developing innate immune therapeutics and diagnostics. This unaudited Form 10-Q covers the quarter and nine months ended September 30, 2023. The company has never generated revenue and does not expect product revenue for several years, if ever.
Programs include REVTx-300, REVTx-100, REVTx-200 and REVTx-99b, and the REVDx-501 diagnostic. Management describes preclinical and clinical-preparation work, particularly for REVTx-300, REVTx-100 and REVTx-200.
Financial performance and position
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Research and development | $1.65 million | $0.38 million | $3.09 million | $5.04 million |
| General and administrative | $1.13 million | $0.82 million | $3.24 million | $4.61 million |
| Total operating expenses / operating loss | $2.78 million | $1.20 million | $6.33 million | $9.65 million |
| Net income (loss) | $(2.63) million | $(1.17) million | $2.08 million | $(9.62) million |
| Basic EPS | $(0.42) | $(1.91) | $0.43 | $(19.61) |
The nine-month 2023 net income was driven by an $8.26 million non-cash gain from remeasuring warrant liabilities, not product revenue or operating profit. Q3 net loss widened year over year as operating expenses increased. No meaningful revenue margin is available because the company reported no revenue.
For the first nine months, operating cash use was $5.28 million, versus $10.27 million in 2022. Financing provided $14.03 million, principally from the February 2023 public offering; cash increased $8.74 million to $13.99 million. At September 30, total assets were $14.22 million, current liabilities $5.40 million, total liabilities $5.40 million, and stockholders’ equity $8.82 million. The balance sheet shows no outstanding debt; cash and cash equivalents were the principal liquid assets. The company reported an accumulated deficit of $23.26 million.
Material changes versus prior period
- Q3 R&D rose $1.27 million year over year, mainly from $1.11 million of other program expenses, including preclinical and clinical-preparation costs.
- Nine-month R&D declined $1.95 million, primarily because REVTx-99a clinical study costs and personnel expenses fell, partly offset by higher program and manufacturing costs.
- Nine-month G&A declined $1.36 million, principally due to lower D&O insurance and professional-service costs; Q3 G&A increased $0.31 million, including higher personnel and advisory/legal costs.
- February 2023’s public offering generated $14.0 million net proceeds. Common shares outstanding increased from 682,882 at December 31, 2022 to 6,297,303 at September 30, 2023, including issuance through offering and warrant exercises. A 1-for-35 reverse split took effect February 1, 2023; share and per-share data are adjusted for it.
- The company issued 6.45 million Class C warrants in the offering. Most were exercised through an alternative cashless mechanism; 487,160 remained outstanding at September 30. These liability-classified warrants are remeasured at fair value, creating potentially volatile non-operating results.
Outlook, risks and unusual items
Management expects substantial operating losses and negative operating cash flows for the foreseeable future, with R&D expenses expected to increase as programs advance. The company states its $14.0 million cash balance is not expected to fund operations for one year after the financial statements’ issuance, raising substantial doubt about its ability to continue as a going concern. It plans to seek additional equity or debt financing but may not obtain funding on acceptable terms or at all; a shortfall could force delays, reductions or termination of development activities. No specific financial guidance was provided.
Nasdaq notified the company of a minimum-bid-price deficiency in August 2023. It had until February 5, 2024 to regain compliance by maintaining a closing bid price of at least $1.00 for 10 consecutive business days, with a possible additional grace period.
Legal matters include a LifeSci Capital claim seeking approximately $2.7 million in cash and $2.6 million in equity for disputed fees; a second summary-judgment motion was pending, and a trial, if needed, was not expected before the second half of 2024. A separate IPO underwriter demanded $655,000. The company recorded $2.91 million of deferred underwriting commissions as a current liability, but states additional liability for the disputed matters cannot be determined. A-IR Clinical Research seeks £1.6 million plus interest and costs over disputed study invoices; no liability was recorded because the amount could not be determined.
Other disclosed exposures include foreign-currency payments, though management says a 10% exchange-rate movement would not materially affect results, and ordinary-course vendor contracts that are generally cancellable. Management said disclosure controls were effective at a reasonable-assurance level and reported no material change in internal control over financial reporting. No material change to the risk factors in the 2022 Form 10-K was reported.
Important facts for investors to verify
- Cash runway and financing needs, including whether the company obtains capital before liquidity becomes insufficient.
- Clinical and preclinical progress, spending plans, and milestones for REVTx-300, REVTx-100, REVTx-200, REVTx-99b and REVDx-501.
- Remaining Class C warrants, potential dilution, and the effect of future fair-value changes on reported earnings.
- Nasdaq bid-price compliance status and any consequences if the company fails to regain or maintain listing compliance.
- Developments in the LifeSci and A-IR disputes, the underwriter demand, and any resulting cash, equity or legal obligations.
- Share count and potential dilution from warrants, options, RSUs or future fundraising.